Language:
  
[Sign in] [Register]   

EIAab logo

Index > News Center > News list.
Enter your KeyWord (Ex. ELISA Kit, Cuticular Active Peptide Factor, etc)
search
Search content in infomation.

Scientists have discovered a protein that is resistant to heart aging

Posted by star on 2018-08-07 18:56:27
Hits:12

   

    Recently, an article named Preserved cardiac function by vinculin enhances glucose oxidation and extends health- and life-span was published in the journal AIP. The researchers found that using genetic engineering technology to improve the level of a protein in drosophila can keep its cardiomyocytes viable and have a long lifespan extend. This study provides new clues for exploring the relationship between heart function, metabolism, and longevity.

    This protein called vinculin, helps cells stick together and acts like a mortar for construction. The heart of many animals increases the production of focal adhesion protein during aging, helping to maintain myocardial structure and delay the decline of heart function.

    The researchers developed a drosophila with multiple copies of the focal adhesion protein gene, which increased the production of focal adhesion protein in cardiomyocytes by 50%. The results showed that these transgenic drosophilae were particularly active, exercise-enhancing, and lived for up to 9 weeks, while common drosophila usually only lives for 6 weeks.

    These transgenic drosophilae also metabolizes glucose faster, which means that high levels of focal adhesion protein can increase the body's efficiency in absorbing nutrients. The researchers used toxic chemicals to interfere with the energy supply of cardiomyocytes and found that transgenic drosophila were much more tolerant than normal drosophila.

    The researchers said that they hope that their work in the future will bring about drugs that help humans improve the expression of focal adhesion protein and help treat heart failure.

    Wuhan EIAab Science Co., Ltd has d......

Scientists have discovered a new kidney cancer kinesin

Posted by star on 2018-08-07 01:37:44
Hits:12

   

    Recently, an article called VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma was published in the journal Science. A potential therapeutic target for kidney cancer with the same genetic variation has been found to be known by scientists to cause excessive blood vessels, which helps to provide nutrition for the tumor. This latest discovery demonstrates a potential new cancer-driven pathway.

    More than 90% of clear cell renal cell carcinoma has a genetic change that leads to the loss of the tumor suppressor gene (VHL). In this new study, the researchers identified a new downstream effect of this genetic change to help promote kidney cancer, and they found that an excessive accumulation of a protein called ZHX2 in these cells contributes to activate other signals that promote cancer growth. These findings suggest that ZHX2 is a potential novel therapeutic target for clear cell renal cell carcinoma.

    Clear cell renal cell carcinoma is one of the most common types of kidney cancer, accounting for approximately 70% of all kidney cancer cases. More than 90% of patients with clear cell renal cell carcinoma has mutations or changes in genes that cause loss of VHL function. When the function of VHL is lost, cells can accumulate signals that trigger blood vessel growth.

    These researchers have developed a screening technique to discover new molecules that may help promote cancer when VHL is lost. This led them to identify kidney cancer cells that lack VHL and usually have more ZHX2. By removing ZHX2 from the laboratory model, they are able to inhibit the growth, infiltration, and spread of cancer cells. In addition, they observed that it is associat......

Apple peel extract can delay the aging process

Posted by star on 2018-08-03 02:01:33
Hits:19

   

    According to the latest issue of Nature Medicine, researchers of Senolytics improve physical function and increase lifespan in old age have found that the combination of dasatinib (a leukemia drug) and quercetin (a extract from apple skin) can make life in older mice Extended by 36%.

    Aging cells usually appear in the human body in their 60s, but appear earlier in obese or chronically ill patients. These abnormal cells are in a state of decline, but they are not willing to die. Some people think that aging cells themselves can catalyze the aging process.

    The research team proved that this is indeed the case. When the researchers injected small amounts of senescent cells into 6-month-old mice, their speed, endurance, and strength dropped by 20% to 50% in a few weeks, almost the same level as a typical 2-year-old mouse.

    To block the effects of aging cells, the team chose a combination of dasatinib and quercetin because both would interfere with the way aging cells avoid death. When the research team administered a combination of drugs to young mice that were aged by infusion into senescent cells, the physical capacity lost by these mice recovered between 50% and 100% in two weeks.

    When the research team administered drugs to older mice between the ages of 24 and 27 months, the speed, endurance and strength of these mice increased by 30% to 100%, and their remaining life was smaller than those who did not. The mouse is 36% long.



ELISA Applied training

Posted by star on 2018-08-01 20:13:58
Hits:15

   

    On the morning of July 31, 2018, Wuhan EIAAB Science co., LTD held a successful training about the application of ELISA kit.

    Zhang Ting who is a member of the technology department mainly introduced the following three aspects to the company personnel: 1. Basic components of the ELISA Kit; 2. Application of ELISA Kit in biomedical science; 3. Application of ELISA in other fields. It mainly consists of three parts of ELISA test, as well as basic knowledge such as different classification according to the analysis principle. Examples are given to explain the applications of ELISA kit, which greatly strengthens the understanding of sales personnel and further clarifies the work content.

    When Zhang Ting explained the related methods of the ELISA kit, everyone listened carefully and also actively participated in the communication. At the end of the presentation, the company personnel asked their own questions and Zhang Ting fluently answered all the questions. And we believe that the spirit and attitude of keeping improving in work with every personnel will certainly make the company go further!



An AIDS vaccine passed an early human trial

Posted by star on 2018-07-31 19:22:11
Hits:13

   

    Animal and early human trials have shown that a new AIDS vaccine is safe and can induce an immune response, and then they will conduct efficacy trials in a wider population.

    Researchers at Harvard University reported Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) in a new issue of the British Lancet that the vaccine is a "mosaic vaccine" that splicing the genes of different HIV strains to target a wider range of HIV. The strain induces an immune response. This is the fifth AIDS vaccine to enter the second phase of clinical efficacy trials in 35 years. Only one of the four vaccines had a protective effect. The AIDS vaccine called RV144 reduced the risk of infection by 31%.

    In the latest trial, researchers recruited 393 healthy adults from countries such as South Africa, Thailand, and the United States, and volunteers were randomized to a “mosaic vaccine” or placebo. The results showed that the vaccine successfully induced an antiviral immune response and the subject was well tolerated.

    Experiments conducted with 72 macaques showed that this "mosaic vaccine" protected 48 of them from being infected with human monkey chimeric immunodeficiency virus (SHIV). The human monkey chimeric immunodeficiency virus is similar to HIV and can infect monkeys.

    Currently, researchers have initiated Phase II clinical efficacy trials in Southern Africa. A total of 2,600 high-risk women with HIV infection are participating, and trial results are expected in 2021 or 2022.



Page 2 of 84
Hot Genes
ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
Top Searches
Ubiquitin ELISA Ubiquitin-protein ligase metalloproteinase Asprosin TRAP1A Tumor necrosis vitamin d
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

Twitter